Bristol-Myers Squibb (NYSE:BMY) Shares Down 0.7%

Bristol-Myers Squibb (NYSE:BMY)’s share price traded down 0.7% during mid-day trading on Wednesday . The stock traded as low as $48.55 and last traded at $48.65. 2,515,820 shares were traded during trading, a decline of 84% from the average session volume of 15,356,469 shares. The stock had previously closed at $48.99.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $61.18.

Bristol-Myers Squibb Stock Performance

The company has a market capitalization of $90.74 billion, a price-to-earnings ratio of 11.58, a PEG ratio of 1.47 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The stock has a 50-day moving average price of $51.13 and a 200-day moving average price of $51.26.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same period in the previous year, the company posted $2.05 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. As a group, analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.36%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Institutional Trading of Bristol-Myers Squibb

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GHP Investment Advisors Inc. grew its holdings in Bristol-Myers Squibb by 6.8% during the 3rd quarter. GHP Investment Advisors Inc. now owns 6,076 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 386 shares in the last quarter. Boston Trust Walden Corp raised its holdings in shares of Bristol-Myers Squibb by 5.3% during the third quarter. Boston Trust Walden Corp now owns 15,258 shares of the biopharmaceutical company’s stock valued at $886,000 after acquiring an additional 771 shares during the last quarter. Strategic Blueprint LLC raised its holdings in shares of Bristol-Myers Squibb by 8.6% during the third quarter. Strategic Blueprint LLC now owns 5,440 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 431 shares during the last quarter. Kempner Capital Management Inc. purchased a new position in Bristol-Myers Squibb during the third quarter worth approximately $2,844,000. Finally, Aaron Wealth Advisors LLC lifted its position in Bristol-Myers Squibb by 30.9% during the third quarter. Aaron Wealth Advisors LLC now owns 134,081 shares of the biopharmaceutical company’s stock worth $7,782,000 after buying an additional 31,622 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.